Published in Obesity and Diabetes Week, March 28th, 2005
Nastech ended 2004 with $74.5 million in cash, cash equivalents and short-term investments compared to $25.1 million at December 31, 2003. In December 2004 Nastech completed the sale of 4.25 million shares of our common stock at $13.50 per share and received net proceeds after expenses of approximately $53.0 million. The company also received a $5.0 million license fee from our alliance with Merck during the quarter.
The net loss for the quarter ended December 31, 2004, was $5.9 million or $0.41 per share, compared to a net loss of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.